Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>Cyclin-dependent kinase 9 (CDK9) is a member of the CDK subfamily and plays a major role in the regulation of transcriptional elongation. It has attracted widespread attention as a therapeutic target for cancer. Here, we aimed to explore novel CDK 9 inhibitors by using a hybrid virtual screening strategy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main methods</h3><p>A hybrid virtual screening strategy was constructed with computer-aided drug design (CADD). First, compounds were filtered in accordance with Lipinski's rule of five and adsorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Second, a 3D-QSAR pharmacophore model was built and used as a 3D query to screen the obtained hit compounds. Third, the hit compounds were subjected to molecular docking studies. Fourth, molecular dynamics (MD) simulations were performed on CDK9 in complex with the final hits to examine the structural stability. Finally, CDK9 kinase biochemical assay was performed to identify the biological activity of the hit compounds.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Key findings</h3><p>Seven hit compounds were screened out. These hit compounds showed drug-like properties in accordance with Lipinski's rule of five and ADMET. Complexes involving the six hit compounds bound to CDK9 exhibited good structural stability in the MD simulation. Furthermore, these six hit compounds had strong inhibitory activity against CDK9 kinase. In particular, hit <strong>3</strong> showed the most promising activity with the percentage of 71%.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>The six hit compounds may be promising novel CDK9 inhibitors, and the hybrid virtual screening strategy designed in this study provides an important reference for the design and synthesis of novel CDK9 inhibitors.</p>

Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation

Potent inhibitors targeting Cyclin-dependent kinase 9 discovered via virtual high-throughput screening and absolute binding free energy calculations

Identification of Potent CDK9 Inhibitors with Novel Skeletons Via Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation

Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening

Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors

Design, synthesis, and biological evaluation of (E)-N′-substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity

Pharmacophore Identification, Docking and "in Silico" Screening for Novel Cdk1 Inhibitors

A Robust Computational Framework for the Optimization of CDK7 Inhibitors as Promising Cancer Therapy

Elucidating Binding Selectivity in Cyclin-Dependent Kinases (CDKs) 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors

Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations

Molecular Principle of the Cyclin-Dependent Kinase Selectivity of 4-(Thiazol-5-yl)-2-(phenylamino) Pyrimidine-5-carbonitrile Derivatives Revealed by Molecular Modeling Studies.

Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors

Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity

Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia

Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations

The Inhibitors of CDK4/6 from a Library of Marine Compound Database: A Pharmacophore, ADMET, Molecular Docking and Molecular Dynamics Study

Structure-Based Drug Design, Synthesis and Antitumor Activities of Novel CDK7 Inhibitors

Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors